Drug Trial Radar · NCT07607925
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Jun 19, 2026
Primary completion
Jan 10, 2030
Study completion Jan 10, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
GSK5926371Drug
GSK5926371 will be administered at different dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: Up to 28 days
- Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severityTime frame: Up to approximately 169 weeks
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Iowa City, Iowa · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Canton, Ohio · Recruiting
GSK Investigational Site
Heidelberg, Victoria, Australia · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
GSK Investigational Site
Tampere, Finland · Recruiting
GSK Investigational Site
Pierre-Bénite, France · Recruiting
GSK Investigational Site
Rennes, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Alessandria, Italy · Recruiting
GSK Investigational Site
Milan, Italy · Recruiting
GSK Investigational Site
Rozzano, MI, Italy · Recruiting
GSK Investigational Site
Aichi, Japan · Recruiting
GSK Investigational Site
Chiba, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Salamanca, Spain · Recruiting
GSK Investigational Site
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.